Salbutamol sulfate

337.39

239.152144

242-424-0

29225090

155.70000

2.12490

Solid

186.91 °C

419.2ºC at 760 mmHg

250 °C

soluble in water and 1M sodium hydroxide (50 mg/ml).1 M NaOH: soluble 50 mg/ml, clear to slightly hazy, yellow-green

Store at RT

8.9X10-9 mm Hg at 25 °C /Estimated/

10.3None

2811

3

43-22

36/37-36

ZE4400000

Xn,Xi

|Warning|H302 (21.36%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P261, P264, P270, P272, P280, P281, P301+P312, P302+P352, P308+P313, P321, P330, P333+P313, P363, P405, and P501|Aggregated GHS information provided by 103 companies from 17 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Prospective studies have shown that ALT elevations occur in less than 1% of patients receiving long term oral therapy with typical beta adrenergic bronchodilators, but instances of clinically apparent liver injury have not been reported in any detail. However, several cases of acute elevations in serum aminotransferase levels have been described in pregnant women receiving high doses of beta adrenergic agents intravenously for prevention or control of premature labor (Case 1). Serum alkaline phosphatase, GGT and bilirubin levels are generally normal or within the normal range for later stages of pregnancy. The serum aminotransferase elevations are usually asymptomatic, but may be associated with nausea and right upper quadrant pain. Bilirubin elevations are minimal and cases with jaundice have not been reported. The abnormalities resolve promptly (within 1 to 3 weeks) upon stopping therapy and have not been associated with fatalities or chronic liver injury.

Treatment of asthma

The beta-2 adrenergic agonists are a large group of drugs that mimic the actions of naturally occurring catecholamines such as norepinephrine, epinephrine and dopamine. Direct agonists directly interact with the adrenergic receptors, whereas indirect agonists typically stimulate the release of endogenous catecholamines. The beta-2 adrenergic agonists act mainly on the smooth muscle of the vasculature, bronchial tree, intestines and uterus. These agents also act on the liver stimulating glycogenolysis and release of glucose from the liver and muscle (particularly if used in high doses). The beta-2 adrenergic agonists are used largely as bronchodilators in the management of asthma, both in control of acute symptomatic attacks as well as chronic, long term prevention and management. These agents are some of the most commonly prescribed drugs for asthma and are widely used and proven to be well tolerated and safe. The use of beta adrenergic agonists in asthma has not been associated with elevations in serum aminotransferase or alkaline phosphatase levels or in causing clinically apparent liver disease. When given in large doses or after intentional overdose, beta adrenergic agonists can cause liver injury. Most case reports of liver damage from these agents have been associated with their use in control of premature labor (for their effects on relaxation of uterine smooth muscle). The liver injury typically arises within a few days of starting high dose intravenous beta adrenergic agonists, is usually asymptomatic, not associated with jaundice, and rapidly reversed once the medication is stopped.

Antiasthmatic Agents

Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS. (See all compounds classified as Adrenergic beta-2 Receptor Agonists.)|Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)|Agents that cause an increase in the expansion of a bronchus or bronchial tubes. (See all compounds classified as Bronchodilator Agents.)

2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol

Human Drugs -> EU pediatric investigation plans|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients|Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients